Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: A series of patients surgically treated at a single institution

被引:252
作者
Gronchi, A
Casali, PG
Mariani, L
Lo Vullo, S
Colecchia, M
Lozza, L
Bertulli, R
Fiore, M
Olmi, P
Santinami, M
Rosai, J
机构
[1] Ist Nazl Studio & Cura Tumori, Dept Surg, I-20133 Milan, Italy
[2] Ist Nazl Studio & Cura Tumori, Dept Med Oncol, I-20133 Milan, Italy
[3] Ist Nazl Studio & Cura Tumori, Dept Biostat, I-20133 Milan, Italy
[4] Ist Nazl Studio & Cura Tumori, Dept Pathol, I-20133 Milan, Italy
[5] Ist Nazl Studio & Cura Tumori, Dept Radiat Oncol, I-20133 Milan, Italy
关键词
D O I
10.1200/JCO.2003.05.150
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To explore prognostic factors in surgically treated aggressive fibromatosis (extra-abdominal desmoid tumor). Patients and Methods: A total of 203 consecutive patients treated with surgery over a 35-year period at a single referral center were retrospectively reviewed. One hundred twenty-eight were first seen at our institution with primary disease, whereas 75 had a recurrent tumor. All patients underwent macroscopically complete resection. Margins were rated as negative in 146 (97 with primary tumors, 49 with recurrences) and positive in 57 (31 in primary, 26 in recurrences) patients. Median follow-up was 135 months. Results: Patients with primary disease had a better disease-free survival rate than those with recurrence (76% v 59% at 10 years). Presenting with a recurrence was also the strongest predictor of local failure in the multivariate analysis. In patients first treated for primary disease, size and site had prognostic significance, whereas microscopically positive surgical margins did not. In contrast, in patients with recurrence, there was a trend toward better prognosis if margins were negative (although this was not significant at multivariate analysis). Conclusion: Presence of microscopic disease does not necessarily affect long-term disease-free survival in patients with primary presentation of extra-abdominal desmoid tumors. Thus, function-sparing surgery may be a reasonable choice when feasible without leaving macroscopic residual disease. In patients with recurrences, positive margins may more clearly affect prognosis, potentially necessitating adjuvant radiation in selected cases. (C) 2003 by American Society of Clinical Oncology.
引用
收藏
页码:1390 / 1397
页数:8
相关论文
共 47 条
[1]   Aggressive fibromatosis (desmoid tumor) is a monoclonal disorder [J].
Alman, BA ;
Pajerski, ME ;
DiazCano, S ;
Corboy, K ;
Wolfe, HJ .
DIAGNOSTIC MOLECULAR PATHOLOGY, 1997, 6 (02) :98-101
[2]  
Anthony T, 1996, J AM COLL SURGEONS, V182, P369
[3]  
Azzarelli A, 2001, CANCER, V92, P1259, DOI 10.1002/1097-0142(20010901)92:5<1259::AID-CNCR1446>3.0.CO
[4]  
2-Y
[5]   Radiation therapy in the management of desmoid tumors [J].
Ballo, MT ;
Zagars, GK ;
Pollack, A .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 42 (05) :1007-1014
[6]   Desmoid tumor: Prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy [J].
Ballo, MT ;
Zagars, GK ;
Pollack, A ;
Pisters, PWT ;
Pollock, RA .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) :158-167
[7]   AGGRESSIVE FIBROMATOSIS - OPTIMIZATION OF LOCAL-MANAGEMENT WITH A RETROSPECTIVE FAILURE ANALYSIS [J].
CATTON, CN ;
OSULLIVAN, B ;
BELL, R ;
CUMMINGS, B ;
FORNASIER, V ;
PANZARELLA, T .
RADIOTHERAPY AND ONCOLOGY, 1995, 34 (01) :17-22
[8]   RECENT TRENDS IN THE MANAGEMENT OF DESMOID TUMORS - SUMMARY OF 19 CASES AND REVIEW OF THE LITERATURE [J].
EASTER, DW ;
HALASZ, NA .
ANNALS OF SURGERY, 1989, 210 (06) :765-769
[9]   CHROMOSOME-ABERRATIONS IN DESMOID TUMORS - TRISOMY-8 MAY BE A PREDICTOR OF RECURRENCE [J].
FLETCHER, JA ;
NAEEM, R ;
XIAO, S ;
CORSON, JM .
CANCER GENETICS AND CYTOGENETICS, 1995, 79 (02) :139-143
[10]   Mutations of adenomatous polyposis coli (APC) gene are uncommon in sporadic desmoid tumours [J].
Giarola, M ;
Wells, D ;
Mondini, P ;
Pilotti, S ;
Sala, P ;
Azzarelli, A ;
Bertario, L ;
Pierotti, MA ;
Delhanty, JDA ;
Radice, P .
BRITISH JOURNAL OF CANCER, 1998, 78 (05) :582-587